Literature DB >> 22950387

A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.

Ivan R Vogelius1, Søren M Bentzen.   

Abstract

INTRODUCTION: The risk of developing side effects after radiotherapy is not only dependent on radiation dose, but may also be affected by patient-related risk factors. Here we perform a literature-based meta-analysis to estimate the effect of various clinical risk factors on the incidence of symptomatic radiation pneumonitis (RP).
MATERIAL AND METHODS: A systematic review of English language articles in the Pubmed, Embase and Cochrane controlled trials registers. Studies with the mesh term "radiation pneumonitis" or the search term "radiation pneumonitis" were included. Additional studies were identified by manual searching of the references. Studies reporting crude incidence or odds ratios (OR) for radiation pneumonitis vs. age, disease location, smoking status, chemotherapy schedule or comorbidity were included. A systematic overview (meta-analysis) was conducted to synthesize data across multiple studies.
RESULTS: Significant risk factors for RP were: older age (OR = 1.7, p < 0.0001); disease located in mid-lower lung (OR = 1.9, p = 0.002); presence of comorbidity (OR = 2.3, p = 0.007). Ongoing smoking was found to protect against RP (OR = 0.6, p = 0.008). History of smoking tended to protect against RP (OR = 0.7, p = 0.06). Sequential (rather than concomitant) chemotherapy scheduling (OR = 1.6, p = 0.01) increased RP risk, but treatment intensity and patients selection are likely confounders.
CONCLUSION: This systematic overview revealed several clinical risk factors for RP that have not been unambiguously identified in the literature. These risk factors should be considered when defining dose-volume constraints for radiation treatment plan optimization.

Entities:  

Mesh:

Year:  2012        PMID: 22950387      PMCID: PMC3557496          DOI: 10.3109/0284186X.2012.718093

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  44 in total

1.  A method to adjust radiation dose-response relationships for clinical risk factors.

Authors:  Ane L Appelt; Ivan R Vogelius
Journal:  Radiother Oncol       Date:  2011-10-06       Impact factor: 6.280

Review 2.  Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.

Authors:  Søren M Bentzen
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

3.  Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer.

Authors:  Y Segawa; N Takigawa; M Kataoka; I Takata; N Fujimoto; H Ueoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

4.  Effects of smoking and irradiated volume on inflammatory response in the lung of irradiated breast cancer patients evaluated with bronchoalveolar lavage.

Authors:  L Bjermer; L Franzén; B Littbrand; K Nilsson; T Angström; R Henriksson
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

5.  Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model.

Authors:  G Gagliardi; J Bjöhle; I Lax; A Ottolenghi; F Eriksson; A Liedberg; P Lind; L E Rutqvist
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

6.  Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

Authors:  A Inoue; H Kunitoh; I Sekine; M Sumi; K Tokuuye; N Saijo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

7.  The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer.

Authors:  H Quon; F A Shepherd; D G Payne; P Coy; N Murray; R Feld; J Pater; A Sadura; B Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-01       Impact factor: 7.038

8.  Risk factors of pneumonitis following chemoradiotherapy for lung cancer.

Authors:  M Yamada; S Kudoh; K Hirata; T Nakajima; J Yoshikawa
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

9.  Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.

Authors:  Alena Novakova-Jiresova; Mieke M Van Gameren; Rob P Coppes; Harm H Kampinga; Harry J M Groen
Journal:  Radiother Oncol       Date:  2004-05       Impact factor: 6.280

10.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer.

Authors:  Yvette Seppenwoolde; Katrien De Jaeger; Liesbeth J Boersma; José S A Belderbos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

View more
  69 in total

Review 1.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 2.  Effect of transforming growth factor-β1 869C/T polymorphism and radiation pneumonitis.

Authors:  Yingtian Wang; Xingguang Wang; Xiyan Wang; Deyong Zhang; Shujuan Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support.

Authors:  Graham W Warren; Samantha Sobus; Ellen R Gritz
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

4.  Relationship between dose-volume parameters and pulmonary complications after neoadjuvant chemoradiotherapy followed by surgery for lung cancer.

Authors:  Shigeo Takahashi; Tetsuhiko Go; Yoshitaka Kasai; Hiroyasu Yokomise; Toru Shibata
Journal:  Strahlenther Onkol       Date:  2016-07-14       Impact factor: 3.621

Review 5.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors:  Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal:  Cancer Discov       Date:  2014-01-17       Impact factor: 39.397

6.  Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship.

Authors:  Peter G Hawkins; Philip S Boonstra; Stephen T Hobson; Jason W D Hearn; James A Hayman; Randall K Ten Haken; Martha M Matuszak; Paul Stanton; Gregory P Kalemkerian; Nithya Ramnath; Theodore S Lawrence; Matthew J Schipper; Feng-Ming Spring Kong; Shruti Jolly
Journal:  Radiother Oncol       Date:  2017-09-23       Impact factor: 6.280

7.  Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models.

Authors:  M Thor; Jo Deasy; A Iyer; E Bendau; A Fontanella; A Apte; E Yorke; A Rimner; A Jackson
Journal:  Radiother Oncol       Date:  2019-05-27       Impact factor: 6.280

8.  Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.

Authors:  Ellen D Yorke; Andrew Jackson; Li Cheng Kuo; Anthonia Ojo; Kelly Panchoo; Prasad Adusumilli; Marjorie G Zauderer; Valerie W Rusch; Annemarie Shepherd; Andreas Rimner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-27       Impact factor: 7.038

9.  Clinical features, outcomes and treatment-related pneumonitis in elderly patients with esophageal carcinoma.

Authors:  Jian He; Zhao-Chong Zeng; Shi-Ming Shi; Ping Yang
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

10.  Validation and optimization of a predictive model for radiation pneumonitis in patients with lung cancer.

Authors:  Charlott Mörth; Ioannis Kafantaris; Markus Castegren; Antonios Valachis
Journal:  Oncol Lett       Date:  2016-06-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.